The great recognition of the drug delivery industry is that technologies don't sell--only drugs do. The result: drug delivery start-ups today must be drug companies, selling their best shot at using their technologies to create highly differentiated drug products. To do so, start-ups are pursuing two different visions. On the one hand are those who try to do as little as possible to the underlying molecule, thereby reducing risk and cost while relying on their system for product differentiation. On the other are those who believe that only important modifications to the molecule, or at least a deep understanding of the biology underlying a specific compound's therapeutic role, permit fundamental improvements in treatment.
By Roger Longman
On the morning of September 30, as Merck & Co. Inc. 's stock was plunging 26%, shares of Nastech...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
Dr Reddy’s CEO discusses the growth opportunity for semaglutide, including production capacity and ‘crazy’ demand indications, and a potential 20-plus product GLP-1 portfolio. All eyes are also on an upcoming hearing in India pertaining to Novo Nordisk’s semaglutide patent in the country.
In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.
The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.
In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.